Trials / Completed
CompletedNCT00654602
48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety
A 48 Week, Open Label, Non-Comparative, Multicentre, Phase IIIb Study to Evaluate the Efficacy and Safety of the Lipid-Regulating Agent Rosuvastatin in the Treatment of Subjects With Fredrickson Type IIa and Type IIb Dyslipidaemia, Including Heterozygous Familial Hypercholesterolaemia.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,500 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of rosuvastatin in reducing low density lipoprotein cholesterol levels to internationally recognised goals in subjects with dyslipidaemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rosuvastatin | |
| BEHAVIORAL | Maintenance of specific diet |
Timeline
- Start date
- 2002-02-01
- Completion
- 2004-11-01
- First posted
- 2008-04-08
- Last updated
- 2009-05-28
Source: ClinicalTrials.gov record NCT00654602. Inclusion in this directory is not an endorsement.